Creative Biolabs is one of the well-recognized experts who are professional in applying hybridoma technology for the production of monoclonal antibodies. Based on our extensive experience and advanced platform, we are proud to offer hybridoma services with different species for our customers all over the world.
Introduction of Hybridoma Technology
Hybridoma technology is a common method for the long-term production of large-scale monoclonal antibodies. Derived from the fusion of specific antibody-producing B lymphoblast with myeloma, the forming of the hybrid cell line is the key part of hybridoma technology. The general development of hybridoma cells starts with animal immunization and then the splenocytes would be harvested. The B cells that produce specific antibodies are isolated and in turn fused with myeloma. The obtained stable fusion cells are known as hybridoma cells, which can express antigen-specific monoclonal antibodies continuously. Monoclonal antibodies are of great value not only in basic research of biology and immunology but also in medical applications. In addition, equipped with other advanced techniques available in Creative Biolabs, such as antibody-drug conjugates (ADCs), hybridoma sequencing, and bioconjugation the extended application of mAbs can further assist the development of either therapeutic or diagnostic agents.
Fig 1. Hybridoma technology.
One-stop Monoclonal Antibody Production by Hybridoma
Features of Hybridoma Services from Creative Biolabs
Creative Biolabs has been a long-term expert in the field of monoclonal antibody generation. Equipped with our advanced hybridoma platform, we are confident in offering various hybridoma services with different species. If you are interested in our services, please do not hesitate to inquire us for more details.
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.